☆ 4.7 Meeting Abstract

Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

ANNALS OF ONCOLOGY (2020)

Journal

ANNALS OF ONCOLOGY

Volume 31, Issue -, Pages S1164-S1165

Publisher

ELSEVIER

DOI: 10.1016/j.annonc.2020.08.2264

Keywords

-

Categories

Oncology

Funding

Agenus Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents

Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh

Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.

CANCER IMMUNOLOGY RESEARCH (2021)

Add to Collection

Review Oncology

RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer

David M. O'Malley, Leslie M. Randall, Camille Gunderson Jackson, Robert L. Coleman, John L. Hays, Kathleen N. Moore, R. Wendel Naumann, Rodney P. Rocconi, Brian M. Slomovitz, Krishnansu S. Tewari, Marek Ancukiewicz, Waldo Ortuzar Feliu, Bradley J. Monk

Summary: Balstilimab and zalifrelimab are promising investigational agents for the treatment of cervical cancer, either alone or in combination. The RaPiDS trial aims to evaluate their safety and efficacy in patients with advanced cervical cancer who have progressed after platinum-based chemotherapy.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Immunology

Targeting immunosuppressive Ly6C+classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance

B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons

Summary: The resistance to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) is associated with infiltrating monocytes, and controlling the differentiation process of monocytes can enhance the therapeutic potential of ICB.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Prachi Bhave, Tasnia Ahmed, Serigne N. Lo, Alexander Shoushtari, Anne Zaremba, Judith M. Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K. Schwarze, Meghan J. Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U. Blank, Egle Ramelyte, Katharina C. Kaehler, Severine Roy, Paolo A. Ascierto, Olivier Michielin, Paul C. Lorigan, Douglas B. Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A. McArthur, Andrew M. Haydon, Georgina Long, Alexander M. Menzies, Matteo S. Carlino

Summary: Acral melanoma is a rare subtype with poor prognosis, and there is a lack of prospective clinical trial evidence on the efficacy of checkpoint inhibitors in this population. The study found that initial anti-PD-1/ipilimumab combination had a significantly higher ORR compared to anti-PD-1 alone, but this benefit did not translate to improved OS in this retrospective cohort. Primary site did not impact treatment outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma

Katie M. Campbell, Meelad Amouzgar, Shannon M. Pfeiffer, Timothy R. Howes, Egmidio Medina, Michael Travers, Gabriela Steiner, Jeffrey S. Weber, Jedd D. Wolchok, James Larkin, F. Stephen Hodi, Silvia Boffo, Lisa Salvador, Daniel Tenney, Tracy Tang, Marshall A. Thompson, Christine N. Spencer, Daniel K. Wells, Antoni Ribas

Summary: Immune checkpoint inhibitors (ICIs) such as CTLA-4 and PD-1-blocking antibodies have significant effects on tumor immune cell infiltration. In this study, we analyzed molecular datasets from 514 patients with advanced melanoma to explore the features of anti-PD-1 response. We found that prior anti-CTLA-4 therapy is associated with genomic and transcriptomic differences in anti-PD-1 responders, suggesting that the tumor microenvironment plays a role in predicting the response to PD-1 blockade therapy.

CANCER CELL (2023)

Add to Collection

Article Oncology

Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma

Cara Haymaker, Daniel H. Johnson, Ravi Murthy, Salah-Eddine Bentebibel, Marc Uemura, Courtney W. Hudgens, Houssein Safa, Marihella James, Robert H. Andtbacka, Douglas B. Johnson, Montaser Shaheen, Michael A. Davies, Shah Rahimian, Srinivas K. Chunduru, Denai R. Milton, Michael T. Tetzlaff, Willem W. Overwijk, Patrick Hwu, Nashat Gabrail, Sudhir Agrawal, Gary Doolittle, Igor Puzanov, Joseph Markowitz, Chantale Bernatchez, Adi Diab

Summary: The combination of intratumoral tilsotolimod and systemic ipilimumab shows promising results in patients with advanced melanoma, with an overall response rate of 22.4% and additional stability in 49% of patients. The phase III clinical trial of this combination is ongoing, indicating potential for improved clinical outcomes in a subset of patients resistant to traditional therapies.

CANCER DISCOVERY (2021)

Add to Collection

Review Immunology

Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action

Zena N. Willsmore, Ben G. T. Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, Robert J. Harris, Alicia Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexa McCraw, Anthony Cheung, Gabriel Osborn, Ricarda M. Hoffmann, Mano Nakamura, Roman Laddach, Jenny L. C. Geh, Alastair MacKenzie-Ross, Ciaran Healy, Sophia Tsoka, James F. Spicer, Debra H. Josephs, Sophie Papa, Katie E. Lacy, Sophia N. Karagiannis

Summary: CTLA-4 and PD-1 are immune checkpoint molecules that are targets of antibody immunotherapies for malignant melanoma. Combination therapy with immune checkpoint inhibitors may have better outcomes compared to monotherapy in certain patient groups, but also presents challenges and increased rates of adverse events.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis

Ze Xiang, Jiayuan Li, Zhengyu Zhang, Chao Cen, Wei Chen, Bin Jiang, Yiling Meng, Ying Wang, Bjoern Berglund, Guanghua Zhai, Jian Wu

Summary: Immunotherapy with immune checkpoint inhibitor (ICI) drugs is a hot topic in cancer treatment. Our study used Bayesian model to comprehensively evaluate the safety and efficacy of ICI drugs. Different ICI drug therapies may have different risks in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Treatment with cemiplimab was found to be the best choice in terms of PFS and OS. Our study provides new insights and strategies for the clinical practice of ICI drugs.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Yoshiyasu Umeda, Shusuke Yoshikawa, Yukiko Kiniwa, Takeo Maekawa, Osamu Yamasaki, Taiki Isei, Shigeto Matsushita, Motoo Nomura, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Tatsuya Takenouchi, Ryo Tanaka, Hiroshi Kato, Atsushi Otsuka, Taisuke Matsuya, Natsuki Baba, Kotaro Nagase, Takashi Inozume, Takehiro Onuma, Yutaka Kuwatsuka, Noriki Fujimoto, Takahide Kaneko, Masazumi Onishi, Kenjiro Namikawa, Naoya Yamazaki, Yasuhiro Nakamura

Summary: The study found that the combination of radiotherapy (RT) with immune checkpoint inhibitors (ICIs) did not result in a significant survival benefit for patients with mucosal melanoma (MUM), although it may help improve local tumor control and relieve local symptoms.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska

Summary: This phase II trial evaluated the efficacy of dual treatment with balstilimab and zalifrelimab in patients with recurrent and/or metastatic cervical cancer. The results showed promising and durable clinical activity, with favorable tolerability, in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC

Rosa Rapuano Lembo, Lorenzo Manna, Guendalina Froechlich, Emanuele Sasso, Margherita Passariello, Claudia De Lorenzo

Summary: This study investigated the effects of anti-PD-L1 or anti-CTLA-4 antibodies on NK and T cell subpopulations in co-cultures with triple negative breast cancer cells. The results showed that the novel immunomodulatory antibodies generated in the laboratory were more effective in activating NK cells compared to the clinically validated antibodies. These findings suggest that antibodies targeting different epitopes can have differential effects on different lymphocyte subpopulations, indicating the potential for novel combinations of monoclonal antibodies to activate both T cells and NK cells in cancer immunotherapy.

CANCERS (2022)

Add to Collection

Article Oncology

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Natasha B. Leighl, Mary W. Redman, Naiyer Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth C. Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Thomas E. Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara

Summary: The study found that the combination of Durvalumab and Tremelimumab had minimal activity in patients with advanced squamous non-small cell lung cancer, especially those who had received prior PD-1 therapy. There were also observed grade ≥ 3 adverse events in a portion of the patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Medicine, Research & Experimental

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

Jiaqi Chen, Ding Zhang, Ying Yuan

Summary: Conversion treatment and salvage surgery can improve outcomes for patients with unresectable locally advanced hepatocellular carcinoma (HCC). The combination of immune checkpoint inhibitors and locoregional therapy is considered the most promising conversion therapy.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

Article Oncology

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Onuma, Motoo Nomura, Yoshiyasu Umeda, Naoya Yamazaki

Summary: This study compared the efficacy of PD-1 and PD-1+CTLA-4 for the treatment of advanced AM in Japanese patients. The results showed no significant differences in ORR, PFS, and OS between the two groups in PSM patients. In NAM patients, the PD-1+CTLA-4 group had significantly higher ORR and longer PFS, and PD-1+CTLA-4 was identified as an independent predictor of favorable PFS in NAM patients.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

Y. Nakamura, K. Namikawa, S. Yoshikawa, Y. Kiniwa, T. Maekawa, O. Yamasaki, T. Isei, S. Matsushita, M. Nomura, Y. Nakai, S. Fukushima, S. Saito, T. Takenouchi, R. Tanaka, H. Kato, A. Otsuka, T. Matsuya, N. Baba, K. Nagase, T. Inozume, N. Fujimoto, Y. Kuwatsuka, M. Onishi, T. Kaneko, T. Onuma, Y. Umeda, D. Ogata, A. Takahashi, M. Otsuka, Y. Teramoto, N. Yamazaki

Summary: In a study of advanced mucosal melanoma patients in Japan, it was found that there was no significant difference in efficacy between PD1 and PD1 + CTLA4, but the latter had a higher incidence of immune-related adverse events.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study

Gilberto de Castro Jr, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M. Kowalski, Hande Z. Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K. Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S. K. Mok, Byoung Chul Cho

Summary: This study presented the 5-year results of the KEYNOTE-042 trial, which showed that pembrolizumab demonstrated long-term clinical benefit compared to chemotherapy in patients with PD-L1-positive, locally advanced/metastatic non-small-cell lung cancer. Regardless of the level of PD-L1 expression, pembrolizumab had a better overall survival rate, confirming its status as a standard of care for this patient population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

Jayesh Desai, Peter Fong, Victor Moreno, Sophia Frentzas, Tarek Meniawy, Ben Markman, Mark Voskoboynik, Tahmina Rahman, Nageshwar Budha, John Wu, Jin Marlow, Silu Yang, Emiliano Calvo, Juan Martin-Liberal

Summary: This study investigated the safety and anti-tumor activity of BGB-A333, a PD-L1 inhibitor, alone and in combination with tislelizumab in patients with advanced solid tumors. The results showed that BGB-A333 in combination with tislelizumab demonstrated promising anti-tumor activity.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study

Ryota Saito, Shunichi Sugawara, Ryo Ko, Koichi Azuma, Ryo Morita, Makoto Maemondo, Satoshi Oizumi, Kazuhisa Takahashi, Hiroshi Kagamu, Yukari Tsubata, Masahiro Seike, Toshiaki Kikuchi, Isamu Okamoto, Morita Satoshi, Hajime Asahina, Kentaro Tanaka, Kenji Sugio, Kunihiko Kobayashi

Summary: This multicenter phase 2 trial assessed the safety and efficacy of osimertinib and platinum-based chemotherapy in previously untreated patients. The results showed that the combination of osimertinib and platinum-based chemotherapy had significant efficacy and acceptable toxicity in EGFR-mutated advanced non-squamous NSCLC patients.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Skeletal muscle morphology in patients receiving primary versus interval cytoreductive surgery for advanced high-grade serous ovarian cancer

Christelle Schofield, Pedro Lopez, Paul A. Cohen, Dennis R. Taaffe, Robert Usher Newton, Daniel A. Galvao, Emily Jeffery, Tarek M. Meniawy, Carolyn J. Peddle-McIntyre

Summary: The study aimed to compare muscle morphology in patients who underwent different surgeries for advanced high-grade serous ovarian cancer and explore the associations with survival outcomes. Skeletal muscle index and density were calculated using CT images of 88 ovarian cancer patients. Results showed that low skeletal muscle index and density were prevalent at diagnosis, with interval surgery patients having significantly lower mean skeletal muscle density than primary surgery patients. Greater reductions in skeletal muscle density during treatment were associated with poorer overall survival. Therefore, supportive care involving resistance exercise and nutrition counseling may help preserve/enhance muscle mass and density.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

Add to Collection

Meeting Abstract Oncology

Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A posthoc analysis of the phase III SUNLIGHT trial

G. Prager, J. Taieb, M. Fakih, F. Ciardiello, E. Van Cutsem, M. E. Elez Fernandez, F. J. S. M. Cruz, L. S. Wyrwicz, Z. Papai, P. G. Poureau, G. Liposits, C. Cremolini, I. Bondarenko, D. P. Modest, E. M. Calleja, L. Roby, V. Barboux, N. Causse-Amellal, J. Tabernero

ANNALS OF ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)

E. Carcereny, E. Felip, M. Majem, B. Doger de Speville, T. D. Clay, I. Bondarenko, J. Peguero, M. Cobo Dols, M. D. Forster, G. Ursol, E. Kalinka, G. M. Garcia Ledo, L. Vila Martinez, W. Iams, M. G. Krebs, J. Kefas, K. Efthymiadis, S. Perera, C. Mueller, F. Triebel

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Oncology

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

Michael Friedlander, Linda Mileshkin, Janine Lombard, Sophia Frentzas, Bo Gao, Michelle Wilson, Tarek Meniawy, Sally Baron-Hay, Karen Briscoe, Nicole McCarthy, Christos Fountzilas, Andres Cervantes, Ruimin Ge, John Wu, Alexander Spira

Summary: The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in previously treated advanced solid tumours. The study showed that pamiparib plus tislelizumab demonstrated a variable level of antitumour activity in patients with advanced solid tumours, with the highest ORR observed in triple-negative breast cancer cases.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study

Myung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, Byoung Chul Cho, Shunichi Sugawara, Gabriella Galffy, Byoung Yong Shim, Nikolay Kislov, Rajnish Nagarkar, Ingel Demedts, Steven J. M. Gans, Dolores Mendoza Oliva, Ross Stewart, Zhongwu Lai, Helen Mann, Xiaojin Shi, Maen Hussein

Summary: The ORION study evaluated the effectiveness of olaparib in combination with durvalumab as maintenance therapy for patients with metastatic NSCLC. The results showed that the combination therapy did not significantly improve progression-free survival compared to durvalumab alone, although there was a numerical improvement.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Ross A. Soo, Byoung Chul Cho, Joo-Hang Kim, Myung-Ju Ahn, Ki Hyeong Lee, Anastasia Zimina, Sergey Orlov, Igor Bondarenko, Yun-Gyoo Lee, Yueh Ni Lim, Sung Sook Lee, Kyung-Hee Lee, Yong Kek Pang, Chin Heng Fong, Jin Hyoung Kang, Chun Sen Lim, Pongwut Danchaivijitr, Saadettin Kilickap, James Chih-Hsin Yang, Cagatay Arslan, Hana Lee, Seong Nam Park, Irfan Cicin

Summary: The study demonstrates that Lazertinib significantly improves intracranial progression-free survival compared with gefitinib in patients with CNS metastases, with more durable responses.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Yurii Osypchuk, Ivan Sinielnikov, Tsai-Sheng Yang, Xiao Liang, Chunxia Chen, Linna Wang, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel

Summary: This study compared the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib with sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. The results showed that camrelizumab-rivoceranib significantly improved progression-free survival and overall survival compared with sorafenib. This provides a new and effective treatment option for patients with unresectable hepatocellular carcinoma.

LANCET (2023)

Add to Collection

Article Obstetrics & Gynecology

The impact of an educational and information systems initiative on somatic BRCA testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia

Andrew Fantoni, Tarek Meniawy, Paul A. Cohen, Michelle McMullen

Summary: Improving education and information systems in Western Australia has led to increased somatic BRCA testing rates for patients with HGSOC.

GYNECOLOGIC ONCOLOGY REPORTS (2023)

Add to Collection

Meeting Abstract Oncology

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

Natalie I. Vokes, David R. Gandara, Ahmet Sezer, Saadettin Kilickap, Mahmut Gumus, Igor Bondarenko, Mustafa Ozguroglu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, Dmitry Bentsion, Jinrui Liu, Nicholas Giangreco, Fang Wang, Siyu Li, Israel Lowy, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Vladimir Jankovic

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Naruto Taira, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial

Julien Taieb, Gerald W. Prager, Marwan Fakih, Fortunato Ciardello, Eric Van Cutsem, Elena Elez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Nadia Amellal, Hasnaa Hassan, Donia Skanji, Josep Tabernero

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3

E. Kalinka, I. Bondarenko, M. Gogishvili, T. Melkadze, A. Baramidze, A. Sezer, T. Makharadze, S. Kilickap, M. Gumus, K. D. Penkov, D. Giorgadze, M. Ozguroglu, X. He, J-F. Pouliot, F. Seebach, I. Lowy, G. Gullo, P. Rietschel

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.